CERENOME, INC. — Form 8-K
Filed October 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Cerenome (NASDAQ: CNSY) released a corporate presentation dated September 30, 2026, detailing its integrated CNS oncology platform. Diagnostically, CNSide achieved 158M contracted covered lives (63% of non-Medicare), expanded from 5 to 24 ordering institutions quarter-over-quarter, and collected 362 commercial specimens year-to-date; Medicare coverage expected January 1, 2027 with rate pending November 2026 CMS decision. Therapeutically, REYOBIQ (rhenium-186 nanoliposome) showed Phase 1a leptomeningeal metastasis (LM) data: 93% CTC response, 76% MRI response, 87% clinical benefit, median OS 9 months; Phase 2 LM interim analysis targeted Q4 2026, GBM Phase 2 topline 1H 2027. The company is building an 11,000+ specimen CSF biobank across 120+ institutions for AI-driven drug discovery and lab efficiency gains (4x diagnostic throughput, 2.8x fewer process errors modeled).
Why this rating
Material diagnostic traction and meaningful therapeutic progress, but primarily status updates on previously announced milestones. Company scale $31.9M; 362 YTD tests and early-stage LM OS data are encouraging but not yet revenue-transformative. No new financing, no major partnership, no regulatory decision. Execution-dependent value.
See more from October 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.